Korean J Med.
2008 Oct;75(4):370-382.
Current status of drug-eluting stents
- Affiliations
-
- 1Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Abstract
- The percutaneous coronary intervention (PCI) has been a great advance in the treatment of coronary artery disease since implantation of bare metal stents (BMS) decreased acute recoil and arterial shrinkage caused by balloon angioplasty. However, neointimal hyperplasia leading to in-stent restenosis after BMS implantation has been emerged a new obstacle. Recent introduction of drug-eluting stents (DES) contributes a powerful breakthrough to PCI. Many large well-controlled randomized trials have shown that DES remarkably reduces restenosis and target vessel revascularization in de novo lesions when compared with BMS. Therefore the application of DES have been expanded to the complex lesions such as left main, multi-vessel, bifurcation, in-stent restenosis, or chronic total occlusion. The safety and effectiveness of DES are still under evaluation with ongoing trials. However, some problems such as very late stent thrombosis remained to be solved. In this review article, we summarize the past, present and future of DES with updated result of clinical trials.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Drug-Eluting Stent Strut Fracture as a Cause of Restenosis
- A Case of Neointimal Calcification in a Drug-Eluting Stent
- Stent Optimization Using Adjunctive Balloon Dilatation in the Era of Second-Generation Drug-Eluting Stents
- Novel Coronary Stent Platforms
- Optical Coherence Tomography-guided Treatment of Multiple Stent Fracture in Patients with Overlapping Drug-eluting Stents
